Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing: 2017 update U Amstutz, LM Henricks, SM Offer, J Barbarino, JHM Schellens, JJ Swen, ... Clinical Pharmacology & Therapeutics 103 (2), 210-216, 2018 | 559 | 2018 |
Clinical relevance of DPYD variants c. 1679T> G, c. 1236G> A/HapB3, and c. 1601G> A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta … D Meulendijks, LM Henricks, GS Sonke, MJ Deenen, TK Froehlich, ... The Lancet Oncology 16 (16), 1639-1650, 2015 | 386 | 2015 |
DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis LM Henricks, CATC Lunenburg, FM de Man, D Meulendijks, ... The Lancet Oncology 19 (11), 1459-1467, 2018 | 361 | 2018 |
Prospective DPYD genotyping to reduce the risk of fluoropyrimidine-induced severe toxicity: Ready for prime time CATC Lunenburg, LM Henricks, HJ Guchelaar, JJ Swen, MJ Deenen, ... European journal of cancer 54, 40-48, 2016 | 142 | 2016 |
Pretreatment serum uracil concentration as a predictor of severe and fatal fluoropyrimidine-associated toxicity D Meulendijks, LM Henricks, BAW Jacobs, A Aliev, MJ Deenen, ... British Journal of Cancer 116 (11), 1415-1424, 2017 | 132 | 2017 |
Translating DPYD Genotype into DPD Phenotype: Using the DPYD Gene Activity Score LM Henricks, CATC Lunenburg, D Meulendijks, H Gelderblom, A Cats, ... Pharmacogenomics 16 (11), 1275-1284, 2015 | 132 | 2015 |
The use of combinations of monoclonal antibodies in clinical oncology LM Henricks, JHM Schellens, ADR Huitema, JH Beijnen Cancer treatment reviews 41 (10), 859-867, 2015 | 114 | 2015 |
DPYD genotype-guided dose individualization to improve patient safety of fluoropyrimidine therapy: call for a drug label update LM Henricks, FL Opdam, JH Beijnen, A Cats, JHM Schellens Annals of Oncology 28 (12), 2915-2922, 2017 | 106 | 2017 |
A cost analysis of upfront DPYD genotype–guided dose individualisation in fluoropyrimidine-based anticancer therapy LM Henricks, CATC Lunenburg, FM de Man, D Meulendijks, ... European Journal of Cancer 107, 60-67, 2019 | 92 | 2019 |
RasGRP1 opposes proliferative EGFR–SOS1–Ras signals and restricts intestinal epithelial cell growth P Depeille, LM Henricks, RAH Van De Ven, E Lemmens, CY Wang, ... Nature cell biology 17 (6), 804-815, 2015 | 71 | 2015 |
Individualized dosing of fluoropyrimidine‐based chemotherapy to prevent severe fluoropyrimidine‐related toxicity: what are the options? JE Knikman, H Gelderblom, JH Beijnen, A Cats, HJ Guchelaar, ... Clinical Pharmacology & Therapeutics 109 (3), 591-604, 2021 | 61 | 2021 |
Development and validation of a rapid and sensitive UPLC–MS/MS method for determination of uracil and dihydrouracil in human plasma BAW Jacobs, H Rosing, N de Vries, D Meulendijks, LM Henricks, ... Journal of Pharmaceutical and Biomedical Analysis 126, 75-82, 2016 | 56 | 2016 |
Effectiveness and safety of reduced‐dose fluoropyrimidine therapy in patients carrying the DPYD*2A variant: A matched pair analysis LM Henricks, LN van Merendonk, D Meulendijks, MJ Deenen, JH Beijnen, ... International Journal of Cancer 144 (9), 2347-2354, 2019 | 53 | 2019 |
Rs895819 in MIR27A improves the predictive value of DPYD variants to identify patients at risk of severe fluoropyrimidine‐associated toxicity D Meulendijks, LM Henricks, U Amstutz, TK Froehlich, CR Largiadèr, ... International journal of cancer 138 (11), 2752-2761, 2016 | 44 | 2016 |
Food‐effect study on uracil and dihydrouracil plasma levels as marker for dihydropyrimidine dehydrogenase activity in human volunteers LM Henricks, BAW Jacobs, D Meulendijks, D Pluim, D van den Broek, ... British Journal of Clinical Pharmacology 84 (12), 2761-2769, 2018 | 37 | 2018 |
Dihydropyrimidine dehydrogenase phenotyping using pretreatment uracil: a note of caution based on a large prospective clinical study M de With, J Knikman, FM de Man, CATC Lunenburg, LM Henricks, ... Clinical Pharmacology & Therapeutics 112 (1), 62-68, 2022 | 32 | 2022 |
Capecitabine‐based treatment of a patient with a novel DPYD genotype and complete dihydropyrimidine dehydrogenase deficiency LM Henricks, EJM Siemerink, H Rosing, J Meijer, SMI Goorden, ... International journal of cancer 142 (2), 424-430, 2018 | 28 | 2018 |
guideline for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing: 2017 update U Amstutz, LM Henricks, SM Offer, J Barbarino, JHM Schellens, JJ Swen, ... Clin Pharmacol Ther 103 (2), 210-6, 2018 | 27 | 2018 |
Patients homozygous for DPYD c.1129-5923C>G/haplotype B3 have partial DPD deficiency and require a dose reduction when treated with fluoropyrimidines D Meulendijks, LM Henricks, ABP van Kuilenburg, BAW Jacobs, A Aliev, ... Cancer chemotherapy and pharmacology 78, 875-880, 2016 | 27 | 2016 |
Treatment Algorithm for Homozygous or Compound Heterozygous DPYD Variant Allele Carriers With Low-Dose Capecitabine LM Henricks, E Kienhuis, FM de Man, AAM van der Veldt, P Hamberg, ... JCO Precision Oncology 1, 1-10, 2017 | 23 | 2017 |